Published in Liver Transpl on September 01, 2006
Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med (2010) 3.09
Exosomes from hepatitis C infected patients transmit HCV infection and contain replication competent viral RNA in complex with Ago2-miR122-HSP90. PLoS Pathog (2014) 2.13
Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J Virol (2007) 1.77
Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci U S A (2007) 1.66
Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog (2012) 1.35
A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology (2011) 1.28
Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Sci Transl Med (2014) 1.22
Griffithsin has antiviral activity against hepatitis C virus. Antimicrob Agents Chemother (2011) 1.14
Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J Virol (2011) 1.13
Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology (2009) 1.12
Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. Am J Transplant (2013) 1.11
The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res (2014) 1.07
Antiviral lectins from red and blue-green algae show potent in vitro and in vivo activity against hepatitis C virus. PLoS One (2013) 1.03
Hepatitis C immune globulin to prevent HCV recurrence after liver transplantation: chasing windmills? Liver Transpl (2006) 0.98
Hepatitis C virus evasion mechanisms from neutralizing antibodies. Viruses (2011) 0.93
Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents. Hepatology (2014) 0.93
Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation. Med Microbiol Immunol (2009) 0.87
Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design. Curr Opin Virol (2015) 0.86
Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. Viruses (2015) 0.84
New insights in recurrent HCV infection after liver transplantation. Clin Dev Immunol (2013) 0.83
A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance. J Virol (2015) 0.83
Strategies to reduce hepatitis C virus recurrence after liver transplantation. World J Hepatol (2013) 0.82
Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation. Liver Transpl (2016) 0.80
Endogenous cytotoxic T-cell response contributes to the long-term antiretroviral protection induced by a short period of antibody-based immunotherapy of neonatally infected mice. J Virol (2007) 0.80
Liver transplantation and hepatitis C. Int J Hepatol (2012) 0.79
Management of Hepatitis C Before and After Liver Transplantation in the Era of Rapidly Evolving Therapeutic Advances. J Clin Transl Hepatol (2014) 0.78
Antibodies to an interfering epitope in hepatitis C virus E2 can mask vaccine-induced neutralizing activity. Hepatology (2015) 0.77
Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization. World J Gastroenterol (2014) 0.76
Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate. Liver Transpl (2016) 0.76
Response-Guided Therapy for Hepatitis C Virus Recurrence Based on Early Protocol Biopsy after Liver Transplantation. J Korean Med Sci (2015) 0.75
State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization. J Immunol Res (2016) 0.75
Update on the Development of Anti-Viral Agents Against Hepatitis C. J Clin Transl Hepatol (2013) 0.75
Prevention of hepatitis C recurrence after liver transplantation: An update. World J Gastrointest Pharmacol Ther (2012) 0.75
NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature (2004) 15.14
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology (2012) 5.47
Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med (2013) 5.29
Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood (2004) 4.04
The H19 non-coding RNA is essential for human tumor growth. PLoS One (2007) 3.75
The auxin influx carrier LAX3 promotes lateral root emergence. Nat Cell Biol (2008) 3.69
Dissecting Arabidopsis lateral root development. Trends Plant Sci (2003) 3.52
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015) 3.13
Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J (2004) 2.94
Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol (2003) 2.88
Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology (2003) 2.66
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology (2004) 2.28
Current epidemiology of hepatitis E virus infection in the United States: low seroprevalence in the National Health and Nutrition Evaluation Survey. Hepatology (2014) 2.27
Cytokinins act directly on lateral root founder cells to inhibit root initiation. Plant Cell (2007) 2.23
Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18
Neuropilin-1 promotes cirrhosis of the rodent and human liver by enhancing PDGF/TGF-beta signaling in hepatic stellate cells. J Clin Invest (2010) 2.06
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure. J Hepatol (2012) 2.05
Auxin cross-talk: integration of signalling pathways to control plant development. Plant Mol Biol (2002) 2.01
Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis (2003) 1.86
Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther (2005) 1.85
Highly upregulated in liver cancer noncoding RNA is overexpressed in hepatic colorectal metastasis. Eur J Gastroenterol Hepatol (2009) 1.85
Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther (2003) 1.76
HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis (2006) 1.70
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. J Hepatol (2013) 1.68
Stable genetic modification of human embryonic stem cells by lentiviral vectors. Mol Ther (2003) 1.68
The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol (2012) 1.61
MicroRNA expression patterns and function in endodermal differentiation of human embryonic stem cells. PLoS One (2008) 1.56
Overproduction of abscisic acid in tomato increases transpiration efficiency and root hydraulic conductivity and influences leaf expansion. Plant Physiol (2007) 1.55
Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transpl (2007) 1.54
Cytokinin regulation of auxin synthesis in Arabidopsis involves a homeostatic feedback loop regulated via auxin and cytokinin signal transduction. Plant Cell (2010) 1.52
IL-6/IL-6R axis plays a critical role in acute kidney injury. J Am Soc Nephrol (2008) 1.48
Excellent outcome of Lamivudine treatment in patients with chronic renal failure and hepatitis B virus infection. J Clin Gastroenterol (2003) 1.46
Neonatology has always been a bargain--even when we weren't very good at it! Acta Paediatr (2007) 1.45
Validation of endogenous reference genes for qRT-PCR analysis of human visceral adipose samples. BMC Mol Biol (2010) 1.42
In vivo evidence suggesting reciprocal renal hypoxia-inducible factor-1 upregulation and signal transducer and activator of transcription 3 activation in response to hypoxic and non-hypoxic stimuli. Clin Exp Pharmacol Physiol (2013) 1.41
The oncofetal H19 RNA connection: hypoxia, p53 and cancer. Biochim Biophys Acta (2010) 1.41
Gene transfer to chicks using lentiviral vectors administered via the embryonic chorioallantoic membrane. PLoS One (2012) 1.40
Retracted Evaluation of long-term treatment effect in a type 1 diabetes intervention trial: differences after stimulation with glucagon or a mixed meal. Diabetes Care (2014) 1.38
Comprehensive gene and microRNA expression profiling reveals a role for microRNAs in human liver development. PLoS One (2009) 1.37
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology (2015) 1.36
Adenosine Methylation in Arabidopsis mRNA is Associated with the 3' End and Reduced Levels Cause Developmental Defects. Front Plant Sci (2012) 1.32
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology (2004) 1.30
A pivotal role of cyclic AMP-responsive element binding protein in tumor progression. Cancer Res (2004) 1.29
Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail. Hepatology (2011) 1.27
Cirrhosis and liver failure in nonalcoholic fatty liver disease: Molehill or mountain? Hepatology (2008) 1.26
Mutant KRAS is a druggable target for pancreatic cancer. Proc Natl Acad Sci U S A (2013) 1.26
Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaks. Proc Natl Acad Sci U S A (2010) 1.26
Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes. Hepatology (2011) 1.25
Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2009) 1.25
Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus. Eur J Immunol (2004) 1.20
IFN-gamma acts on T cells to induce NK cell mobilization and accumulation in target organs. J Immunol (2006) 1.19
A plant-derived recombinant human glucocerebrosidase enzyme--a preclinical and phase I investigation. PLoS One (2009) 1.19
Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology (2003) 1.18
Increased microRNA activity in human cancers. PLoS One (2009) 1.18
Involvement of the CXCL12/CXCR4 pathway in the recovery of skin following burns. J Invest Dermatol (2006) 1.17
A role for nonsense-mediated mRNA decay in plants: pathogen responses are induced in Arabidopsis thaliana NMD mutants. PLoS One (2012) 1.17
Gene therapy platform for bone regeneration using an exogenously regulated, AAV-2-based gene expression system. Mol Ther (2004) 1.17
Multiple adaptive mechanisms to chronic liver disease revealed at early stages of liver carcinogenesis in the Mdr2-knockout mice. Cancer Res (2006) 1.16
Role of caspase-8 in hepatocyte response to infection and injury in mice. Hepatology (2007) 1.15
Effect of the Colorless non-ripening mutation on cell wall biochemistry and gene expression during tomato fruit development and ripening. Plant Physiol (2004) 1.15
Medicago truncatula CYP716A12 is a multifunctional oxidase involved in the biosynthesis of hemolytic saponins. Plant Cell (2011) 1.15
Chemokines in hepatitis C virus infection: pathogenesis, prognosis and therapeutics. Cytokine (2007) 1.14
Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice. Blood (2003) 1.13
MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates. Gastroenterology (2009) 1.11
Lentiviral vectors harboring a dual-gene system allow high and homogeneous transgene expression in selected polyclonal human embryonic stem cells. Mol Ther (2006) 1.10
Femtosecond infrared laser-an efficient and safe in vivo gene delivery system for prolonged expression. Mol Ther (2003) 1.08
CD4+CXCR4highCD69+ T cells accumulate in lung adenocarcinoma. J Immunol (2006) 1.08
CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol (2010) 1.07
Interaction between CXCR4 and CCL20 pathways regulates tumor growth. PLoS One (2009) 1.07
Clinical problem-solving. Search for the complication. N Engl J Med (2006) 1.07
IFN-gamma treatment at early stages of influenza virus infection protects mice from death in a NK cell-dependent manner. J Interferon Cytokine Res (2010) 1.07
Toll-like receptor 3 signaling attenuates liver regeneration. Hepatology (2009) 1.06
A3 adenosine receptors and mitogen-activated protein kinases in lung injury following in vivo reperfusion. Crit Care (2006) 1.03
Serum protein N-glycans profiling for the discovery of potential biomarkers for nonalcoholic steatohepatitis. J Proteome Res (2009) 1.00
Iatrogenic transmission of hepatitis C virus (HCV) by an anesthesiologist: comparative molecular analysis of the HCV-E1 and HCV-E2 hypervariable regions. Clin Infect Dis (2007) 1.00
Molecular mechanisms of liver carcinogenesis in the mdr2-knockout mice. Mol Cancer Res (2007) 0.99
Development and validation of a disease-targeted quality of life instrument in chronic hepatitis B: the hepatitis B quality of life instrument, version 1.0. Hepatology (2007) 0.99
The hepatitis C virus (HCV)-Trimera mouse: a model for evaluation of agents against HCV. J Infect Dis (2002) 0.99
Evidence for the ectopic synthesis of melanin in human adipose tissue. FASEB J (2008) 0.98
TLR3 signaling in a hepatoma cell line is skewed towards apoptosis. J Cell Biochem (2007) 0.98
Differences in health-related quality of life scores after orthotopic liver transplantation with respect to selected socioeconomic factors. Liver Transpl (2011) 0.98
The role of oncogenic viruses in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis (2011) 0.98
Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003. Stem Cells (2007) 0.97
Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat (2013) 0.97
A novel high throughput screening assay for HCV NS3 serine protease inhibitors. J Virol Methods (2003) 0.96
Molecular imaging of the skeleton: quantitative real-time bioluminescence monitoring gene expression in bone repair and development. J Bone Miner Res (2003) 0.96
Buckle fractures of the distal radius are safely treated in a soft bandage: a randomized prospective trial of bandage versus plaster cast. J Pediatr Orthop (2005) 0.96
HCV tumor promoting effect is dependent on host genetic background. PLoS One (2009) 0.95